Business context and reporting period
The supplied filing is Acasti Pharma Inc.’s Form 10-K, not a filing identified as Grace Therapeutics, Inc. It covers the fiscal year ended March 31, 2020, including the three months ended that date. Amounts below are U.S. dollars unless stated otherwise. Acasti changed from IFRS to U.S. GAAP and retrospectively changed its reporting currency from Canadian dollars to U.S. dollars.
Acasti is a clinical-stage biopharmaceutical company developing CaPre, a krill-oil-derived omega-3 candidate for severe hypertriglyceridemia. It reported no product revenue. Its business prospects depend substantially on CaPre’s clinical and regulatory progress.
Financial performance and position
| Metric | FY2020 / March 31, 2020 | Prior comparable period |
|---|---|---|
| Revenue | No product revenue reported | No product revenue reported |
| Operating loss | $24.438 million | $34.406 million |
| Net loss | $25.513 million; $0.30 per share | $39.366 million; $0.73 per share |
| Non-GAAP operating loss | $22.315 million | $30.555 million |
| Operating cash used | $22.944 million | $24.787 million |
| Cash and cash equivalents | $14.240 million | $16.871 million |
| Current assets / current liabilities | $16.079 million / $7.395 million | $27.966 million / $13.668 million |
| Working capital | $8.684 million | $14.296 million |
| Total assets / total liabilities | $22.853 million / $9.859 million | $36.896 million / $25.851 million |
| Total shareholders’ equity | $12.994 million | $11.045 million |
Research and development expense fell to $15.974 million from $29.373 million, mainly as the Phase 3 program progressed toward completion. Sales and marketing expense increased to $2.665 million from $0.494 million as commercial staffing expanded; general and administrative expense increased to $5.799 million from $4.539 million. There is no meaningful reported gross margin because the company had no product sales.
The fourth quarter reported net income of $16.615 million, versus a $12.690 million net loss a year earlier. The change chiefly reflected a $20.646 million net financial gain, primarily from the fair-value movement in warrant liabilities, and lower R&D expense. The quarter’s accounting gain does not indicate product profitability.
Cash decreased by $2.631 million during FY2020. Investing activities provided $8.138 million, primarily from maturities of investments; financing provided $13.176 million, including $6.981 million net proceeds from ATM share sales and $7.706 million from warrant exercises, partly offset by $1.556 million to repay convertible debentures at maturity. No material conventional funded debt remained at year-end; derivative warrant liabilities were $2.393 million and the convertible debentures had been repaid.
Material changes and business developments
- TRILOGY 1 did not meet statistical significance for its primary triglyceride endpoint. Topline results showed a 30.5% median reduction with CaPre versus 27.5% with placebo at 12 weeks.
- Post-hoc TRILOGY 1 analysis using a revised baseline and a subset meeting the triglyceride threshold found a 28.1% median reduction with CaPre versus 15.4% with placebo at 12 weeks; the difference was not statistically significant (p=0.29). These exploratory analyses do not replace the prespecified pivotal analysis.
- TRILOGY 2 remained blinded at filing. The company expected topline results by the end of August 2020; the FDA required pivotal efficacy analyses using the full intent-to-treat population and supported exploratory post-hoc TRILOGY 1 analyses.
- The FDA indicated that an additional clinical study might still be needed before an NDA. The filing’s planned early-2021 NDA timing assumed no additional study; management said one could delay approval and launch by at least 18–24 months.
- The company signed a two-year fixed-price RKO supply agreement with Aker. Remaining commitment at year-end was approximately $2.8 million, under a take-or-pay arrangement.
Outlook, risks and unusual items
Management estimated that existing cash would fund operating and capital requirements through the first calendar quarter of 2021, but stated it needed additional financing to pursue NDA filing, manufacturing scale-up and pre-commercial activities. The filing states there is substantial doubt about the company’s ability to continue as a going concern. The ATM is conditional, not assured funding. Subsequent to year-end, the company sold 2.279 million shares through the ATM for approximately $1.8 million net, at an average price of about $0.81.
Key risks include uncertain TRILOGY 2 results and FDA acceptance of any pooled data; potential further trials; financing and dilution; manufacturing scale-up and third-party supply dependence; competition and pricing/reimbursement; COVID-19-related disruption and capital-market access; and intellectual-property challenges. Acasti had not regained Nasdaq’s minimum-bid-price compliance by the filing date; temporary relief extended the stated deadline to at least November 9, 2020.
Unusual items include the large quarter-end warrant fair-value gain that drove reported quarterly net income, a $0.738 million equity-settled former-CEO legal settlement, and the transition to U.S. GAAP and U.S.-dollar reporting. The auditor’s opinion was unqualified, but highlighted the going-concern uncertainty.
Most important facts for investors to verify
- Confirm the issuer and reporting period: this document identifies Acasti Pharma Inc. and FY ended March 31, 2020, despite the request metadata naming Grace Therapeutics and “2019 Q4.”
- Track TRILOGY 2 results and the FDA’s position on the full ITT analysis, possible data pooling, and any additional study or NDA requirements.
- Assess cash runway, subsequent ATM proceeds, future financing needs and dilution; the filing identifies substantial going-concern doubt.
- Reconcile figures before relying on them: the risk-factor text cites FY2020 net loss of $26.3 million and accumulated deficit of $129.4 million, while the audited statements report net loss of $25.513 million and accumulated deficit of $126.340 million.
- Evaluate whether manufacturing scale-up, RKO supply, commercialization plans and Nasdaq listing compliance remain on track.